MALAT1 and breast cancer: When patients diagnosed with all BC molecular subtypes (Luminal A/B, HER2 and basal-like/TNBC) were analyzed together, there were no statistically significant differences in Disease-Specific Survival (DSS) between patients whose tumors displayed high or low MALAT1 expression, irrespective of the specific percentile cutoff value employed (data not shown).